Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma ...

Astellas Pharma Inc. rose the most in more than three months after quarterly profit exceeded analysts’ projections, driven by robust sales of its Padcev cancer treatment and Mirabegron used to control ...

On Tuesday, Merck & Co. Inc. (NYSE:MRK) released topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for ...

Astellas has reached Phase 1 testing with ASP3082, an internally developed drug candidate designed to degrade a cancer target called KRAS G12D. Mutated versions of this protein are found in ...

Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy ...

Astellas Pharma US Inc., the U.S. division of Tokyo-based Astellas Pharma Inc., will officially open its $150 million corporate campus Monday in Northbrook, a site that will serve as the […] ...